Delayed Diagnosis and Evolving Trends in Gastric Cancer During and After COVID-19: A Comparative Study of Staging, Helicobacter pylori Infection and Bleeding Risk in Western Romania

Diagnostics, Journal Year: 2025, Volume and Issue: 15(8), P. 950 - 950

Published: April 9, 2025

Background and Objectives: Gastric cancer (GC) remains a leading cause of mortality worldwide, the COVID-19 pandemic posed new barriers in diagnosis management. This study aimed to assess whether pandemic-related healthcare disruptions resulted more advanced GC stages at presentation. We additionally examined role Helicobacter pylori (H. pylori) across non-cardia (NCGC) versus cardia (CGC) evaluated risk factors upper gastrointestinal (GI) bleeding. Methods: A retrospective cohort 121 adult patients with was enrolled from tertiary Gastroenterology Unit Western Romania, spanning pre-pandemic (March 2018-February 2020), 2020-February 2022), post-pandemic 2022-February 2024) periods. Demographic profiles, TNM staging, histopathology, H. status, clinical outcomes-including GI bleeding-were extracted medical records. Results: An increase (Stage III-IVB) noted period (69.4% vs. 53.3% pre-pandemic; p = 0.021). positivity remained higher NCGC (70.6%) compared CGC (44.6%; overall 0.041); however, cases showed rise prevalence (36.4% 55.6%). One-year driven by an stage (hazard ratio [HR] 2.74, 0.002), during (HR 1.66, 0.010), age ≥70 years 1.88, 0.043). Conclusions: Our findings demonstrate that delayed diagnostic endoscopy correlated proportion phase. strongly linked NCGC, though increasing trend prevalence. Patients on antithrombotic agents faced increased bleeding risks.

Language: Английский

---

Temporal trends in cross-country inequalities of early-onset pancreatic cancer: a comprehensive analysis for the global burden of disease study 2021

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 28, 2025

By 2040, pancreatic cancer is expected to become the second leading cause of cancer-related deaths in U.S., with early-onset (EOPC) cases rising among adolescents and young adults. This study uses global burden disease (GBD) 2021 dataset examine global, regional, national EOPC trends predicts through 2050. The analysis covers from 1990 2021, focusing on age-standardized prevalence rate (ASPR), incidence (ASIR), mortality (ASMR), disability-adjusted life years (ASDR). Annual percentage change (APC) average annual (AAPC) were calculated via joinpoint regression. Clustering frontier based sociodemographic index (SDI) assessed link between development levels health outcomes. We used WHO-recommended equity methods quantify disparities applied a Bayesian age-period-cohort (BAPC) model project trends. In rose 42,254, 73% increase 1990, while reached 26,996, up 57%. Although ASIR, ASMR, ASDR declined, ASPR (EAPC = 0.1). Central Eastern Europe had highest burden, fastest growth Australasia 2.78) Western Sub-Saharan Africa 2.25). Males about double females, though female increased. widening gap low- high-SDI regions especially concerning. While currently affects countries most, there clear trend over time showing gradual shift towards low-SDI countries. 2050, ASPR, are projected stabilize, increasing until 2036, then decreasing. High-SDI bear disproportionately high significant diagnostic management challenges, particularly Europe. Rising highlights need identify differences risk factors across develop targeted prevention control strategies.

Language: Английский

---

The viral oncogenesis of COVID-19 and its impact on cancer progression, long-term risks, treatment complexities, and research strategies

Exploration of Medicine, Journal Year: 2025, Volume and Issue: 6

Published: April 28, 2025

The interaction between cancer and coronavirus disease 2019 (COVID-19) poses significant challenges, particularly for immunocompromised individuals who are at heightened risk acute infections long-term complications. pandemic has exacerbated existing vulnerabilities in care by disrupting treatment protocols delaying diagnoses, leading to worsened health outcomes. This article emphasizes the importance of investigating potential impact severe respiratory syndrome 2 (SARS-CoV-2) on progression highlights need effective strategies protect this high-risk population. Long-term consequences, including emergence long COVID, further emphasize ongoing surveillance comprehensive healthcare planning patients during after pandemics. A multifaceted approach is essential, incorporating vaccination, timely therapeutic interventions, sustained support with lingering symptoms. also discusses urges continued research into oncogenic risks associated SARS-CoV-2, which crucial enhancing our understanding broader implications COVID-19 informing public aimed safeguarding future Moreover, data collection development refined clinical guidelines vital improving patient outcomes preparing systems crises. Additionally, mechanisms SARS-CoV-2 may increase susceptibility, chronic inflammation, cellular senescence, immune dysregulation. Understanding these elucidating virus’s potential, among survivors infections. Ensuring continuity resilience global crises requires mitigate disruptions, enhance access screenings treatments, address specific challenges faced experiencing COVID.

Language: Английский

---

Association Between Pre‐Diagnostic Delay and Survival Among Patients With Esophageal and Gastric Cancer Treated With Curative Intent During the COVID19 Pandemic

Cancer Medicine, Journal Year: 2025, Volume and Issue: 14(9)

Published: May 1, 2025

ABSTRACT Background The majority of esophageal and gastric cancers are diagnosed at an advanced stage with poor overall survival (OS). Whether the pre‐diagnostic interval from symptom onset has any impact on OS is unclear. We investigated this question in peri‐COVID19 pandemic era. Methods retrospectively analyzed a cohort 308 patients esophageal, gastroesophageal junction, or carcinoma treated curative intent Princess Margaret Cancer Centre January 2017 to December 2021. Clinical details pertaining initial presentation were determined through retrospective chart review. Cox proportional hazards regression models used assess association between intervals OS, adjusting for baseline patient characteristics. Results median diagnosis was 98 days (IQR 47–169 days). Using cox hazard model, prolonged not associated worse (HR 1.00, p = 0.62). Comparing before during COVID19 pandemic, there notable increase diagnostic delay increasing 92 126 ( 0.007). Median age time 69.6 vs. 64.7 pandemic. Linear showed squamous cell histology significantly 0.04), but did hold true multivariable model. Looking other metrics, no changes treatment versus (median 1.7 weeks both), change resection those who underwent surgery. Conclusion caused significant presenting cancer. lack correlation may reflect underlying tumor biology as driving force that determines prognosis.

Language: Английский

---

GLUT1 Maintains Esophageal Cancer Stem Cell-like Characteristics by Inhibiting Autophagy-dependent Ferroptosis via EGFR

Experimental Cell Research, Journal Year: 2025, Volume and Issue: unknown, P. 114600 - 114600

Published: May 1, 2025

Language: Английский

---

COVID-19 Pandemic–Related Outcomes in High-Risk Gastrointestinal Cancers—Beyond the Numbers

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(3), P. e240143 - e240143

Published: March 5, 2024

Lauren M. Janczewski, MD, MS; Amanda E. Browner, Joseph H. Cotler, PhD; Bryan Palis, MA; Kelley Chan, MD; Rachel Joung, David J. Bentrem, Ryan P. Merkow, Daniel Boffa, MBA; Heidi Nelson, MD

Language: Английский

---

The impact of the California state lockdown during the COVID‐19 pandemic on management of patients with pancreatic ductal adenocarcinoma

Journal of Surgical Oncology, Journal Year: 2024, Volume and Issue: 130(2), P. 276 - 283

Published: June 18, 2024

Abstract Background and Objectives The SARS‐COVID‐19 pandemic significantly limited healthcare access. We sought to evaluate whether California's lockdown in March 2020 affected staging time treatment of pancreatic ductal adenocarcinoma (PDAC). hypothesized that patients diagnosed after the would have longer higher stage at presentation. Methods retrospectively identified categorized 1294 presenting five University California systems with a new diagnosis PDAC into “pre‐lockdown” “post‐lockdown” groups based on timing pathologic diagnosis. Results In 12 months pre‐lockdown, 835 were PDAC, 459 6 post‐lockdown. Demographics, staging, type similar between eras. There was decreased male:female ratio post‐ versus pre‐lockdown (0.97 vs. 1.25; p = 0.03). Time from symptom onset first increased among females post‐lockdown ( 0.001). However, overall shorter era (median 23 26 days, < Conclusions COVID‐19 did not delay initial presentation, diagnosis, or newly patients. Reduced utilization for minor complaints telehealth may contributed.

Language: Английский

---

Delayed surgery during the Covid-19 pandemic did not affect long-term outcomes of pancreatic adenocarcinoma

Surgical Oncology, Journal Year: 2024, Volume and Issue: 58, P. 102169 - 102169

Published: Nov. 23, 2024

Language: Английский

---

From Past to Pandemic: Health Disparities in U.S. Hepatobiliary Cancer Mortality Before and During COVID-19

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 5, 2024

Language: Английский

---

COVID-19 and cancer: reflections 2 years into the pandemic

Korean Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 20(2), P. 47 - 50

Published: Dec. 30, 2024

The COVID-19 pandemic, which emerged in the light of day toward end 2019, has changed almost every field health care basically, and oncology is no exception. After reflecting on events past 2 years, it becomes evident that while pandemic put several difficulties way cancer diagnosis, treatment, research, also brought about a few positive changes once again highlighted how strong global community is.

Language: Английский

---